L1.13 cells were treated with 500nM AZD-6244 for 1h and then solubilized. The array included: ErbB1, ErbB2, ErbB3, ErbB4, FGF R1, FGF R2a, FGF R3, FGF R4, Insulin R, IGF-I R, ALK, Axl, Dtk, Mer, HGF R, MSP R, PDGF Ra, PDGF Rb, SCF R, Flt-3, M-CSF R, c-Ret, ROR1, ROR2, Tie-1, Tie-2, TrkA, TrkB, TrkC, VEGF R1, VEGF R2, VEGF R3, MuSK, EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6, DDR1, DDR2 and RYK. Phospho-tyrosine antibodies decorated the duplicate spots where MET was captured (frame number 2). All other RTKs tested were negative with the exception of EGFR (frame number 1). Black dots outside the frames are references. PP2A silencing.
L1.13 cells were transfected with 2 specific siRNAs targeting PP2A (siRNA#58 and siRNA#59) and a control non-targeting siRNA (Scrambled). Left: total RNAs were isolated and the relative levels of PP2A were analyzed by quantitative RT-PCR analysis. PP2A levels were normalized against the GUSB housekeeping gene. Both siRNAs downregulated PP2A mRNAs by approximately 8-fold. Right: immunoblotting analysis shows that both PP2A-specific siRNAs induced an almost complete protein downregulation (80%-90% as assessed by densitometry).
Vinculin was used as a loading control. CCND1 DNMT3A FBXW7 HSP90B1 MEN1 NOTCH4 RAD51C  SRC  MAPK1  AIP  CCNE1  DPYD  FGFR1  IDH1  MET  NPM1  RAD51D  STAG2  MST1R  AKT1  CDC73  EGFR  FGFR2  IDH2  MGMT  NRAS  RAF1  STK11  AXL  AKT2  CDH1  EPCAM  FGFR3  IGF1R  MLH1  NSD1  RB1  SUFU  TYRO3  AKT3  CDK4  ERBB2  FGFR4  IGF2  MLL  NTRK1  RECQL4  TCF7L1  MERTK  ALK  CDK6  ERBB3  FH  IGF2R  MPL  NTRK2  RET  TCF7L2  ROR1  AMER1  CDK8  ERBB4  FHIT  IKZF1  MRE11A NTRK3  RHBDF2  TET2  ROR2  APC  CDKN1C ERCC1  FLCN  JAK1  MSH2  PALB2  RNF43  TGFBR2  KMT2D  AR  CDKN2B ERCC3  FOXL2  JAK3  MTHFR PBRM1  RUNX1  TNFAIP3 SMARCA4  ARAF  CDKN2A ERCC2  FLT3  JAK2  MSH6  PAX5  ROS1  TMEM127 RICTOR  ARID1A CDKN2C ERCC4  G6PD  KDR  MTOR PDGFRA  SBDS  TP53  LRP1B  ARID1B  CEBPA  ERCC5 GALNT12 KIAA1804 MUTYH PDGFRB SDHAF2  TPMT  FGF10  ASXL1  CEP57  EXT1  GATA1  KIT  MYC  PHOX2B  SDHB  TSC1  NCOR1  ATM  CHEK2  EXT2  GATA2  KRAS  MYCL1  PIK3CA  SDHC  TSC2  KDM5C  ATRX  CREBBP  EZH2  GNA11  LMO1  MYCN  PIK3CD  SDHD  TSHR  CCND2  AURKA CTNNB1 FANCA  GNAQ  MAP2K1 MYD88 PIK3R1 SEMA3D  TYMS  MCL1  BAP1  CYLD  FANCB  GNAS  MAP2K2  NAV2  PMS1  SF3B1  UGT1A1  BLM  CYP1A2 FANCC  GPC3  MAP2K4  NBN  PMS2  SKP2  VHL  BMPR1A CYP2C19 FANCD2 GREM1  MAPK11 NCOA3  POLE  SLX4  VKORC1  BRAF  CYP2C9 FANCE  HMGA1 MAPK12  NF1  POLD1  SMAD2  WRN  BRCA1 CYP2D6 FANCF  HMGA2  MAML1  NF2  PRF1  SMAD3  WT1  BRCA2  DAXX  FANCG  HNF1A  MAX  NKX2-1 PRKAR1A SMAD4  XPA  BRIP1  DDB2  FANCI  HRAS  MDM2 NOTCH1 PTCH1 SMARCB1  XPC  BUB1B  DICER1  FANCL HSP90AA1 MDM4 NOTCH2  PTEN  SMO  XRCC1  CBL  DIS3L2 FANCM HSP90AB1 MED12 NOTCH3 PTPN11  SOX9  MAPK3   Table S1 .
ABL1

NGS Analysis of a panel of 241 cancer genes by NGS.
L1.13 resulted to be BRAF (G469A) and SMO (R726Q) mutated.
